| Item Type | Name |
|
Concept
|
Antitubercular Agents
|
|
Academic Article
|
Management of drug-resistant tuberculosis.
|
|
Academic Article
|
Challenging the management of drug-resistant tuberculosis - Authors' reply.
|
|
Academic Article
|
Perspective for Precision Medicine for Tuberculosis.
|
|
Academic Article
|
Tuberculosis prevention in children: a prospective community-based study in South Africa.
|
|
Academic Article
|
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
|
|
Academic Article
|
Serial measurements of transrenal mycobacterial DNA as indicators of the early bactericidal activity (EBA) of antituberculosis drugs.
|
|
Academic Article
|
Time to culture positivity and sputum smear microscopy during tuberculosis therapy.
|
|
Academic Article
|
Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.
|
|
Academic Article
|
Novel drugs against tuberculosis: a clinician's perspective.
|
|
Academic Article
|
MDR-TB in Eastern Europe in the era of the TB elimination action framework.
|
|
Academic Article
|
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
|
|
Academic Article
|
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
|
|
Academic Article
|
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
|
|
Academic Article
|
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
|
|
Academic Article
|
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.
|
|
Academic Article
|
High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
|
|
Academic Article
|
Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation.
|
|
Academic Article
|
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
|
|
Academic Article
|
Personalized medicine for patients with MDR-TB.
|
|
Academic Article
|
High Rates of Treatment Success in Pulmonary Multidrug-Resistant Tuberculosis by Individually Tailored Treatment Regimens.
|
|
Academic Article
|
Relapse-free cure from multidrug-resistant tuberculosis in Germany.
|
|
Academic Article
|
Extensively drug-resistant tuberculosis in long-term travellers.
|
|
Academic Article
|
Attitudes about tuberculosis prevention in the elimination phase: a survey among physicians in Germany.
|
|
Academic Article
|
Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis.
|
|
Academic Article
|
Revising the definition of extensively drug-resistant tuberculosis.
|
|
Academic Article
|
Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment.
|
|
Academic Article
|
Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control.
|
|
Academic Article
|
Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing.
|
|
Academic Article
|
[Tuberculosis].
|
|
Academic Article
|
Risk Assessment of Tuberculosis in Contacts by IFN-? Release Assays. A Tuberculosis Network European Trials Group Study.
|
|
Academic Article
|
Emergence of bedaquiline resistance in a high tuberculosis burden country.
|
|
Academic Article
|
Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.
|
|
Academic Article
|
Diagnosis and treatment of latent infection with Mycobacterium tuberculosis.
|
|
Academic Article
|
Pan-tuberculosis regimens: an argument against.
|
|
Academic Article
|
Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.
|
|
Academic Article
|
Tuberculosis endotypes to guide stratified host-directed therapy.
|
|
Academic Article
|
[Tuberculosis].
|
|
Academic Article
|
New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?
|
|
Academic Article
|
[Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)].
|
|
Academic Article
|
Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.
|
|
Academic Article
|
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation.
|
|
Academic Article
|
Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study.
|
|
Academic Article
|
The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement.
|
|
Academic Article
|
Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.
|
|
Academic Article
|
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.
|
|
Academic Article
|
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
|
|
Academic Article
|
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
|
|
Academic Article
|
WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis.
|
|
Academic Article
|
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.
|
|
Academic Article
|
Bifunctional T-cell-derived cytokines for the diagnosis of tuberculosis and treatment monitoring.
|
|
Academic Article
|
Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing.
|
|
Academic Article
|
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
|
|
Academic Article
|
[Tuberculosis in adulthood - The Sk2-Guideline of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of adult tuberculosis patients].
|
|
Academic Article
|
A revolution in the management of multidrug-resistant tuberculosis.
|
|
Academic Article
|
Availability and costs of medicines for the treatment of tuberculosis in Europe.
|
|
Academic Article
|
A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.
|
|
Academic Article
|
Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
|
|
Academic Article
|
Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.
|
|
Academic Article
|
Treatment outcomes of MDR-TB and HIV co-infection in Europe.
|
|
Academic Article
|
Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
|
|
Academic Article
|
Multidrug-resistant tuberculosis in Europe, 2010-2011.
|
|
Academic Article
|
Consensus not yet reached on key drugs for extensively drug-resistant tuberculosis treatment.
|
|
Academic Article
|
Availability of anti-tuberculosis drugs in Europe.
|
|
Academic Article
|
Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.
|
|
Academic Article
|
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
|
|
Academic Article
|
Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova.
|
|
Academic Article
|
[Treatment of tuberculosis: what is new?]
|
|
Academic Article
|
Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis.
|
|
Academic Article
|
Changes in treatment for multidrug-resistant tuberculosis according to national income.
|
|
Academic Article
|
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
|
|
Academic Article
|
Impact of Mycobacterium tuberculosis strain type on multidrug-resistant tuberculosis severity, Republic of Moldova.
|
|
Academic Article
|
More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
|
|
Academic Article
|
Time to revise WHO-recommended definitions of MDR-TB treatment outcomes.
|
|
Academic Article
|
Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
|
|
Academic Article
|
What about existing databases?
|
|
Academic Article
|
Multidrug-resistant tuberculosis in Ukraine at a time of military conflict.
|
|
Academic Article
|
Diagnostic performance of the AID line probe assay in the detection of Mycobacterium tuberculosis and drug resistance in Romanian patients with presumed TB.
|
|
Academic Article
|
Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study.
|
|
Academic Article
|
Tuberculosis: current state of knowledge: an epilogue.
|
|
Academic Article
|
Emerging bedaquiline-resistant tuberculosis.
|
|
Academic Article
|
[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)].
|
|
Academic Article
|
Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
|
|
Academic Article
|
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
|
|
Academic Article
|
Multidrug-resistant tuberculosis.
|